Buyback Spend for Vertex Pharmaceuticals (VRTX)
Buyback Spend for Vertex Pharmaceuticals (VRTX): headline value $2.02B · YoY +71.4%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingBuyback SpendSwitch metric
Latest period
$2.02B
YoY change
+71.4%
5Y CAGR
+30.2%
Peak year (2025)
$2.02B
Latest annual
$2.02B
Buyback Spend history chart for Vertex Pharmaceuticals (VRTX) from 1991 to 2025
Buyback Spend history table for Vertex Pharmaceuticals (VRTX) from 1991 to 2025
| Fiscal year | Period ended | Reported | Buyback Spend | YoY |
|---|---|---|---|---|
| 2025 | $2.02B | +71.4% | ||
| 2024 | $1.18B | +175.3% | ||
| 2023 | $427.60M | — | ||
| 2022 | $0 | -100.0% | ||
| 2021 | $1.43B | +164.4% | ||
| 2020 | $539.14M | +180.8% | ||
| 2019 | $192.01M | -45.1% | ||
| 2018 | $350.04M | — | ||
| 2017 | $0 | — | ||
| 2016 | $0 | — | ||
| 2015 | $0 | — | ||
| 2014 | $0 | — | ||
| 2013 | $0 | — | ||
| 2012 | $0 | — | ||
| 2011 | $0 | — | ||
| 2010 | $0 | — | ||
| 2009 | $0 | — | ||
| 2008 | $0 | — | ||
| 2007 | $0 | — | ||
| 2006 | $0 | — | ||
| 2005 | $0 | — | ||
| 2004 | $0 | — | ||
| 2003 | $0 | — | ||
| 2002 | $0 | — | ||
| 2001 | $0 | — | ||
| 2000 | $0 | — | ||
| 1999 | $0 | — | ||
| 1998 | $0 | — | ||
| 1997 | $0 | — | ||
| 1996 | $0 | — | ||
| 1995 | $0 | — | ||
| 1994 | $0 | — | ||
| 1993 | $0 | — | ||
| 1992 | $0 | — | ||
| 1991 | $0 | — |
Buyback Spend values are taken from Vertex Pharmaceuticals's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
In 2025, Vertex Pharmaceuticals (VRTX) buyback spend totalled $2.02B – surged 71.4% year-over-year.
Through 2020–2025 (5 years), Vertex Pharmaceuticals buyback spend delivered a +30.2% annualised rate; sustaining 3 straight years of year-over-year growth.
The dataset's maximum buyback spend sits at $2.02B (2025); the minimum reading of $0 dates to 1991.
Vertex Pharmaceuticals (VRTX) sits 5th of 8 Healthcare peers we track on this metric, against a peer median of $2.75B.
Vertex Pharmaceuticals Buyback Spend by Year
Vertex Pharmaceuticals Buyback Spend 2025: $2.02B
Vertex Pharmaceuticals buyback spend in 2025 was $2.02B, surged 71.4% from 2024. This figure represents the highest annual value in the available history.
Vertex Pharmaceuticals Buyback Spend 2024: $1.18B
Vertex Pharmaceuticals buyback spend in 2024 was $1.18B, surged 175.3% from 2023.
Vertex Pharmaceuticals Buyback Spend 2023: $427.60M
Vertex Pharmaceuticals buyback spend in 2023 was $427.60M.
Vertex Pharmaceuticals Buyback Spend 2022: $0
Vertex Pharmaceuticals buyback spend in 2022 was $0, plunged 100.0% below 2021.
Vertex Pharmaceuticals Buyback Spend 2021: $1.43B
Vertex Pharmaceuticals buyback spend in 2021 was $1.43B.
See more financial history for Vertex Pharmaceuticals (VRTX).
Sector peers — Buyback Spend
Companies in the same sector as Vertex Pharmaceuticals, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $5.54B | Healthcare |
| Merck & Co., Inc. (MRK) | $5.08B | Healthcare |
| Eli Lilly and Company (LLY) | $4.11B | Healthcare |
| Novo Nordisk A/S (NVO) | $1.39B | Healthcare |
| AbbVie Inc. (ABBV) | $980.00M | Healthcare |
| AstraZeneca PLC (AZN) | $719.66M | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
Frequently asked questions
What is Vertex Pharmaceuticals's buyback spend?
Latest reported buyback spend for Vertex Pharmaceuticals (VRTX) is $2.02B (period ending December 31, 2025).
How has Vertex Pharmaceuticals buyback spend changed year-over-year?
Vertex Pharmaceuticals (VRTX) buyback spend changed +71.4% year-over-year on the latest annual filing.
What is the long-term growth rate of Vertex Pharmaceuticals buyback spend?
Vertex Pharmaceuticals (VRTX) buyback spend compound annual growth rate is +30.2% over the most recent 5 years available.
When did Vertex Pharmaceuticals buyback spend hit its highest annual value?
Vertex Pharmaceuticals buyback spend reached its highest annual value of $2.02B in 2025.
What was Vertex Pharmaceuticals buyback spend in 2024?
Vertex Pharmaceuticals (VRTX) buyback spend in 2024 was $1.18B.
What was Vertex Pharmaceuticals buyback spend in 2025?
Vertex Pharmaceuticals (VRTX) buyback spend in 2025 was $2.02B.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
VRTX Overview
Company profile, financial tools, and key metrics
VRTX Revenue Counter
Earns $381.74 every second. See per minute, hour, and day.
VRTX Earnings Counter
Earns $125.36 per second net profit. See per minute, hour, and day.
VRTX Economic Scale
Exceeds Somalia, Fed. Rep.'s GDP. Compare with world economies.
VRTX What If Invested
What if you had invested $1,000? See historical returns from any date.
VRTX How It Makes Money
Discover visual breakdown of $12.04B in revenue — where it comes from and where it goes.
VRTX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
VRTX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
VRTX Daily Price Character
Explosive · 48.3% historical win rate (green days). Streaks & record days.
VRTX Buybacks
1.75% TTM buyback yield. Shareholder yield & SBC comparison.
VRTX Stock Split History
1 split on record. Dates, ratios, and cumulative multiple.